FDA Adverse Event Summary report: N

TERUFLEX

MDR report key: 2693469 · Received August 13, 2012

Report

Report Number
1722028-2012-00575
Date Received
August 13, 2012
Date of Event
July 16, 2012
Report Date
July 16, 2012
Manufacturer
TERUMO BCT
Product Code
KSR
Report Source
Manufacturer report
Reporter Location
CA, US
Reporter Occupation
OTHER

Narratives

Additional Manufacturer Narrative · 1

(B)(4). THE DEVICE PRODUCT CODE 'KSR' WAS USED. INVESTIGATION: THE CUSTOMER STATED THAT SHE KNEW WHICH DEVICE CAUSED THE HEMOGLOBINURIA, SHE WAS JUST DOING HER DILIGENCE IN MENTIONING THE INCIDENT TO ALL VENDORS. THE DISPOSABLE SET WAS NOT RETURNED FOR INVESTIGATION. FOUR RETENTION SAMPLES WERE VISUALLY EXAMINED. TWO RETENTION SAMPLE BAGS WERE USED FOR SOLUTION VOLUME TESTS AND SOLUTION COMPOSITION QUANTITATIVE TESTS. NONE OF THE TESTING SHOWED ABNORMALITIES WITH THE RETENTION SAMPLES. THE DEVICE MANUFACTURING, TESTING AND INSPECTION RECORDS WERE REVIEWED FOR THIS LOT. NO ABNORMALITIES WERE FOUND. ROOT CAUSE: THE ROOT CAUSE COULD NOT BE CONCLUSIVELY DETERMINED. HEMOGLOBINURIA CAN BE CAUSED BY A PATIENT'S DISEASE STATE, HEMOLYTIC TRANSFUSION REACTION, OR HEMOLYSIS OF BLOOD UNIT PRIOR TO TRANSFUSION. HEMOLYSIS OF THE BLOOD UNIT PRIOR TO TRANSFUSION IS COMMONLY CAUSED BY THE FOLLOWING FACTORS: CHARACTERISTICS OF BLOOD - A DONOR COULD HAVE RED BLOOD CELL FRAGILITY, BACTERIAL CONTAMINATION, EXCESSIVE COOLING - BLOOD IS GRADUALLY CONGEALED AND EVENTUALLY HEMOLYZED IF IT IS COOLED BELOW -3C.

Description of Event or Problem · 1

THE CUSTOMER REPORTED THAT A PATIENT DEVELOPED HEMOGLOBINURIA POST-PROCEDURE. THE CUSTOMER DECLINED TO PROVIDE PATIENT INFORMATION. THE DISPOSABLE SET IS UNAVAILABLE FOR RETURN FOR EVALUATION. THIS REPORT IS BEING FILED DUE TO INSUFFICIENT INFORMATION PROVIDED AT THIS TIME TO DETERMINE IF A MALFUNCTION WITH THE POTENTIAL FOR DEATH OR INJURY OCCURRED.

Devices

Seq Brand Generic Product Code Manufacturer Model Lot UDI-DI
1 TERUFLEX TERUFLEX BLOOD BAG KSR TERUMO BCT 120216GB

Patients

Seq Age Sex Outcome Treatment
1